Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INCB160058 |
Synonyms | |
Therapy Description |
INCB160058 binds to JAK2 V617F and inhibits dimerization and cytokine-independent kinase activity, which potentially decreases tumor growth (Blood (2023) 142 (Supplement 1): 860). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB160058 | INCB-160058|INCB 160058 | JAK2 Inhibitor 19 | INCB160058 binds to JAK2 V617F and inhibits dimerization and cytokine-independent kinase activity, which potentially decreases tumor growth (Blood (2023) 142 (Supplement 1): 860). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F | hematologic cancer | predicted - sensitive | INCB160058 | Preclinical | Actionable | In a preclinical study, INCB160058 inhibited tumor growth in a mouse model of hematologic cancer expressing JAK2 V617F (Blood (2023) 142 (Supplement 1): 860). | detail... |
JAK2 V617F | myelofibrosis | predicted - sensitive | INCB160058 | Preclinical - Patient cell culture | Actionable | In a preclinical study, INCB160058 decreased Stat5 phosphorylation, abnormal megakaryopoiesis, and colony formation in human hematopoietic stem cells derived from patients with myelofibrosis harboring JAK2 V617F in culture (Blood (2023) 142 (Supplement 1): 860). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06313593 | Phase I | INCB160058 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Recruiting | USA | 0 |